Vascular Inflammation and Cholesterol Lowering Therapy

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02941016

Enrollment

Registered

2016-10-21

Start date

2016-10-31

Completion date

2020-10-01

Last updated

2020-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipid Lowering, Vascular Inflammation

Brief summary

This study aim to detect change in vascular inflammation following intense lipid lowering therapy

Interventions

DRUGEvolocumab or Alirocumab

All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* treatment with PCSK-9 inhibitors

Exclusion criteria

* Infection Pregnancy Severe claustrophobia Weight \>140 kg

Design outcomes

Primary

Measure	Time frame	Description
Change in vascular inflammation	12 weeks	Change in standard uptake value (SUV) of flourdeoxyglucose (FDG) before and after initiation of lipid lowering therapy

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026